Ibogaine and Mescaline: Where Do They Stand Legally?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Individuals curious about these substances, founders considering business models that involve them, researchers, and anyone who has encountered them in the context of addiction treatment or spiritual practice and wants to understand their legal status.

The short answer

Both ibogaine and mescaline are Schedule I controlled substances under federal law. Neither is part of any currently licensed state program for supervised therapeutic use. Both sit outside the psilocybin-centered conversation that dominates most public discussion of psychedelic reform — and both have distinct legal situations that deserve separate treatment.

Ibogaine

Federal status

Ibogaine is Schedule I under the Controlled Substances Act. The DEA enforces it as such, and as of 2026, no federal exemption exists for its therapeutic use. It cannot be prescribed by any physician. Possession without DEA authorization is a federal crime. Forty-six states and the District of Columbia classify ibogaine as a Schedule I controlled substance under their own laws.

Any researcher who wants to study ibogaine must obtain a Schedule I researcher registration from the DEA, which requires institutional support and compliance with strict storage, handling, and disposal requirements. The FDA must also authorize any clinical trial involving ibogaine before it can proceed with human subjects.

The cardiac safety issue

Ibogaine carries a well-documented cardiac risk. The compound is a potent blocker of cardiac potassium channels, which can cause QT interval prolongation — a delay in the heart’s electrical cycle that can lead to serious arrhythmias and, in some cases, sudden death. Published scientific literature has documented fatalities temporally associated with ibogaine administration, primarily in unregulated settings where cardiac monitoring was absent. Most reported deaths involved individuals with underlying heart conditions, concurrent use of other substances, or both.

This cardiac risk is not peripheral to ibogaine’s regulatory situation — it is central to it. The FDA requires all drugs to demonstrate cardiac safety, and QT interval prolongation is one of the most common reasons compounds fail during drug development. The FDA has not approved ibogaine for any use.

State research funding

Despite its federal Schedule I status, ibogaine has attracted significant state-level research investment in 2024 and 2025, driven largely by its anecdotal reputation as a treatment for opioid use disorder and PTSD.

In June 2025, Texas Governor Greg Abbott signed Senate Bill 2308 into law, allocating $50 million for FDA-regulated clinical trials of ibogaine for opioid use disorder, PTSD, and traumatic brain injury. In December 2025, UTHealth Houston and UTMB Health were awarded that funding to lead the trials. In June 2025, Arizona appropriated $5 million for ibogaine Phase I clinical trials through House Bill 2871. California’s AB 1103, signed by Governor Newsom in October 2025, streamlines the state’s approval process for federally authorized clinical research involving Schedule I and II substances, which covers ibogaine research.

None of this creates legal access to ibogaine for individuals. These are research funding programs. The substance remains Schedule I, and access is limited to participants in properly authorized clinical trials.

International access

Ibogaine treatment clinics operate in Mexico, the Bahamas, Costa Rica, the Netherlands, South Africa, and New Zealand. Mexico has no regulations governing ibogaine, which has made it a destination for treatment centers — though the absence of formal oversight means clinical standards vary significantly. In New Zealand and South Africa, ibogaine can be legally prescribed by a licensed physician. These are the primary legal options for Americans seeking ibogaine access, as no domestic pathway exists.

Traveling to an international clinic carries its own legal and practical considerations. Federal law does not change because the treatment occurred abroad. The lack of regulatory oversight at many international facilities means the cardiac risks that make ibogaine challenging for FDA approval are often unmitigated.

Mescaline

Federal status

Mescaline is Schedule I under the Controlled Substances Act. It is the primary psychoactive compound in the peyote cactus and is also found in San Pedro, Bolivian Torch, Peruvian Torch, and other cacti. It can be produced synthetically. Synthetic mescaline is Schedule I with no exemptions. Plant-derived mescaline is also Schedule I, with one significant exception.

The peyote exemption for the Native American Church

Federal law contains a specific, narrow exemption for the non-drug use of peyote in bona fide religious ceremonies of the Native American Church. This exemption was codified in implementing regulations following the CSA’s enactment, and the American Indian Religious Freedom Act Amendments of 1994 formally strengthened protections for NAC members who use peyote as a sacrament.

The exemption applies to members of the Native American Church for ceremonial religious purposes only. It does not extend to non-Native Americans, even those claiming spiritual use. It does not extend to mescaline derived from other cacti. It does not cover synthetic mescaline. Anyone who manufactures or distributes peyote to the NAC must register annually with the DEA and remain in compliance with CSA requirements.

State laws on peyote vary. Most states mirror the federal exemption. Some states extend the exemption to any bona fide religious use of peyote, including by non-tribal members. A few states impose additional requirements beyond what federal law requires — Texas, for example, limits the exemption to Native American Church members with at least 25% Indian heritage. California has no peyote exemption in statute but courts have recognized First Amendment protections for bona fide religious use.

Mescaline outside the peyote context

San Pedro cactus is legal to purchase, sell, and possess in the United States when the stated intent is ornamental. The cactus itself is not a controlled substance. Mescaline, the compound, is. Possessing San Pedro for the purpose of extracting or consuming mescaline would constitute possession of a Schedule I controlled substance.

Colorado’s decriminalization

Colorado’s Natural Medicine Health Act, passed by voters as Proposition 122 in 2022, decriminalized personal possession, use, and cultivation of mescaline derived from non-peyote cacti for adults 21 and older. Peyote-derived mescaline was excluded from the decriminalization due to conservation concerns about wild peyote populations. This decriminalization applies to personal use only under Colorado state law. Mescaline remains Schedule I federally, and the Colorado decriminalization provides no federal protection.

A handful of cities — including Oakland, Santa Cruz, and others — have passed resolutions making enforcement of laws against possession and use of entheogenic plants, including mescaline-containing cacti, a low priority for law enforcement. These are policy statements, not legal protections.

No state regulated program for mescaline

No state has created a regulated supervised-access program for mescaline comparable to Oregon’s or Colorado’s psilocybin programs. Colorado’s Natural Medicine Health Act authorized the Natural Medicine Advisory Board to recommend adding mescaline (excluding peyote) to the licensed regulated program after June 1, 2026. That recommendation has not yet been made, and no mescaline licensed healing center access currently exists.

What both have in common

Both ibogaine and mescaline are Schedule I substances with no current legal clinical pathway in the United States. Neither has received FDA Breakthrough Therapy designation. Neither is part of a state licensed therapeutic program. Anyone who encounters an offer to access either substance in a domestic therapeutic, ceremonial, or wellness context outside of a properly authorized clinical trial or the specific NAC peyote exemption is operating in illegal territory under federal law — and usually under state law as well.

The research picture for ibogaine is more active than for mescaline, with multiple state-funded clinical trial programs now underway. Whether that research will eventually support an FDA approval pathway for ibogaine is an open question the cardiac safety issue leaves unresolved.

When public information may be enough

If your question is where ibogaine and mescaline sit under current law, this article covers that. For more on how the Schedule I classification works and what it means practically, see What is a DEA Schedule I substance and what does that mean practically?. For how the regulated model works in Oregon and Colorado for psilocybin, see Oregon psilocybin services explained for clients and Colorado natural medicine explained for participants.

When you should speak with a lawyer

You should speak with a lawyer when ibogaine or mescaline is not just a topic of curiosity but touches a decision you are making. That includes:

You are considering traveling internationally for ibogaine treatment and want to understand what legal considerations apply
You are a researcher interested in ibogaine and want to understand the DEA registration and FDA authorization process
You are a founder considering a business model involving either substance and need to understand your actual federal and state exposure
You have been charged with or are under investigation for possession or distribution of either substance
You are a member of a religious community that uses mescaline or peyote ceremonially and want to understand the scope of the legal exemption

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.